Prostatectomy vs Radiation for high risk prostate cancer presented by University Hospitals upcoming faculty Soumyajit Roy (Soum) #GU25 🧍‍♂️ Individual patient data from phase III RCT ⬇️ Decreased risk of metastasis with XRT + ADT compared to prostatectomy 🔜 Prospective trials needed

TALAPRO2 - Talazoparib + Enza vs Placebo vs Enza #GU25 🔑 OS was key secondary endpoint ☠️ 20% reduction of death (45 vs 37 months) in Tala/Enza arm in unselected patients 🧬 HRR-deficient had greatest benefit but trend toward improved OS in non-HRR deficient subset

#GU25 Updates on checkmate 274 trial for adjuvant nivolumab presented by Matt Milowsky 🚨 OS benefit in patients with MIBC (even greater with PD-L1 >= 1% 🧪 Better DFS in patients without prior NAC 🧬 Greater magnitude of DFS benefit w prior NAC OncoAlert Bladder Cancer Advocacy Network

#GU25 Updated NIAGARA results presented by brando 🎆 Continued EFS, OS benefit w perioperative Durvalumab + chemo 🔎 Exploratory analysis: PFS & OS benefit in pts w pCR & non-pCR ❓What is contribution of post-cystectomy durva, esp after pCR OncoAlert Bladder Cancer Advocacy Network

#GU25 Perioperative Trial w Disitimab Vedotin + Toripalimab 🧪 HER2 positive (1+/2+/3+ IHC) ‼️ 63.6% pCR 👏 92.5% 12 mo EFS ⚡️ 21% peripheral neuropathy 🗞️ HER2 is promising target 🔜 With effective ADCs, bladder preservation studies needed OncoAlert Bladder Cancer Advocacy Network

Can an immune response score with prognostic and predictive value in urothelial carcinoma be calculated from RNA expression data? Jason Brown discusses results from a validation cohort of ~6400 UC cases from the Caris clinicogenomic database during #GU25.

Gearing up for #ASCO25 this week!

Tour de force discussion of results of CLONEVO IIT by Dr. Bishoy M. Faltas #ASCO25 💊 Abemaciclib with 31% downstaging rate is cis-ineligible MIBC 🧬 CCND1 amp as biomarker of response ⬇️ Ki-67 and pRB, meeting primary endpoint 🔜 Use in conjunction with EV?

SURE-02 trial of SG + pembro in MIBC presented by Andrea Necchi #ASCO25 🔪 Included option for bladder preservation 🔔 44% cCR, 100% metastasis free survival if cCR 🧬 ERBB2 alt associated with response. MTAP loss with non-response

My Case Comp Cancer Ctr colleague Shilpa Gupta presenting analysis of responders from EV-302 #ASCO25 ⬆️ Duration of response to EV/pembro amongst responders 🩻 74% maintain CR at 2 years on EV/P 💊 Median 12-13 cycles EV amongst responders ❓ Can we de-escalate safely in EV/P responders?

Witty discussion of frontline metastatic UC abstracts by Jacqueline T. Brown, MD #ASCO25 Many developments in this area since the platinum days and potentially changes to come with MIBC trials, de-escalation studies, and triplets under investigation

CtDNA exploratory analysis from NIAGARA by Tom Powles #ASCO25 👨‍🔬 CtDNA + decreased after neoadjuvant chemo and prior to cystectomy 🧬 CtDNA - is favorable prognostic factor 🧹 Better outcomes with CtDNA clearance than persistence 🔪 CtDNA + post-cystectomy = poor prognosis

Great to see an old friend doing great science. Congratulations Curt! #ASCO25

Our own Angela Jia presenting her excellent insights into prostate cancer abstracts #ASCO25 University Hospitals Case Comp Cancer Ctr

Results of AMPLITUDE study of abiraterone/prednisone/niraparib in metastatic hormone sensitive prostate cancer ➕ Positive study ⬇️ rPFS by almost 50 percent in BRCA1/2 patients 🦴 Decreased time to symptomatic progression 🧬 Genomic testing is critical!

What a great day for service! University Hospitals Seidman Cancer Center GU team volunteers with the Kids' Book Bank ! Pedro C Barata, MD MSc FACP Jason Brown

Case CCC ASCO Review - Moshe Ornstein MD dropping wisdom about bladder and kidney cancer Case Comp Cancer Ctr Cleveland Clinic University Hospitals

Lots has happened in prostate cancer over the past year 🎵 ARANOTE - darolutamide in mHSPC ⚡️ AMPLITUDE - niraparib-abiraterone in mHSPC 💦 SPLASH - 177LuPNT2002 in mCRPC I discussed all this and more at the Case CCC ASCO Review today Case Comp Cancer Ctr University Hospitals